Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

75 exposure days is the magic number in inhibitor risk

van den Berg HM et al. EAHAD 2019, Abstract OR05.

Key clinical point: For previously untreated patients with severe hemophilia A, the risk of developing Factor VIII alloantibodies becomes negligible after 75 exposure days.

Major finding: Less than 1% of infants with severe hemophilia A developed inhibitors after 75 exposure days.

Study details: An observational study involving 1,038 previously untreated patients with severe hemophilia A, of which 899 (87%) were followed until 75 exposure days.

Disclosures: Dr. van den Berg reported having no relevant financial disclosures.

Read the Article.

Citation:

van den Berg HM et al. EAHAD 2019, Abstract OR05.